MIM
ROIV icon

MetLife Investment Management’s Roivant Sciences ROIV Stock Holding History

MetLife Investment Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.71M Sell
217,718
-3,658
-2% -$108K 0.03% 467
2026
Q1 		$6.13M Buy
221,376
+8,068
+4% +$207K 0.03% 538
2025
Q4 		$4.63M Sell
213,308
-7,142
-3% -$141K 0.02% 661
2025
Q3 		$3.34M Sell
220,450
-5,546
-2% -$68.7K 0.02% 833
2025
Q2 		$2.55M Sell
225,996
-7,746
-3% -$84K 0.02% 880
2025
Q1 		$2.36M Sell
233,742
-8,295
-3% -$89.7K 0.01% 964
2024
Q4 		$2.86M Buy
242,037
+16,717
+7% +$198K 0.02% 865
2024
Q3 		$2.6M Buy
225,320
+46,879
+26% +$534K 0.01% 889
2024
Q2 		$1.89M Buy
178,441
+108,259
+154% +$1.19M 0.01% 999
2024
Q1 		$740K Buy
70,182
+49,399
+238% +$533K 0.01% 1465
2023
Q4 		$233K Buy
+20,783
New +$203K ﹤0.01% 2155
2023
Q3 		– Sell
-14,438
Closed -$146K – 2964
2023
Q2 		$146K Buy
+14,438
New +$129K ﹤0.01% 2459

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

MetLife Investment Management's ROIV Position: Q2 2026 in Review

MetLife Investment Management reduced its Roivant Sciences (ROIV) stake by 1.7% in Q2 2026, selling an estimated $108K and leaving 217,718 shares worth $7.71M. The position accounts for 0.03% of the portfolio, ranked #467.

MetLife Investment Management first reported a position in ROIV in Q2 2023 and has held it in 12 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • MetLife Investment Management held 217,718 shares of Roivant Sciences worth $7.71M as of Q2 2026.
  • MetLife Investment Management sold 3,658 Roivant Sciences shares in Q2 2026, an estimated $108K.
  • Roivant Sciences made up 0.03% of MetLife Investment Management's portfolio in Q2 2026, its #467 holding.
  • MetLife Investment Management first reported a position in Roivant Sciences in Q2 2023 and has held it in 12 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.